EPISODE · Apr 4, 2022 · 30 MIN
More Complex Cultures
from New Matter: Inside the Minds of SLAS Scientists · host SLAS
In this first podcast of our series on new technologies, we welcomed back Iscaffpharma by chatting with Per Setterberg, CEO and Professor Göran Landberg, CMO. Göran talks to us about how pre-clinical testing in human tumor microenvironment and synthetic copies of the same adds value to drug screening of oncology drugs. The model creates a pre-clinical fingerprint that mimics the potential effect a drug will have in humans, as well as reduces the need for animal models. Dive in with us as we go in depth into the use of 3D printed scaffolds in cancer drug screening, the ethical considerations behind removing the use of animal models, and what future advances they see in using their technology. Iscaffpharma is a Bio-Tech company focusing on developing better treatments of aggressive cancers. To learn more about their research and work, check out their publications here. Upcoming Events:SLAS Meet-UpsLeiden, Netherlands (10 September 2026)Tübingen, Germany (20 October 2026)SLAS 2026 Sample Management Symposium (October 21-22, 2026 | South San Francisco, California)SLAS2027 International Conference & Exhibition (January 30 - February 3, 2027 | San Diego, California)View the full events calendar
Embed this episode
What this episode covers
In this first podcast of our series on new technologies, we welcomed back Iscaffpharma by chatting with Per Setterberg, CEO and Professor Göran Landberg, CMO. Göran talks to us about how pre-clinical testing in human tumor microenvironment and synthetic copies of the same adds value to drug screening of oncology drugs. The model creates a pre-clinical fingerprint that mimics the potential effect a drug will have in humans, as well as reduces the need for animal models. Dive ...
NOW PLAYING
More Complex Cultures
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.